265 related articles for article (PubMed ID: 30868297)
1. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
[TBL] [Abstract][Full Text] [Related]
2. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
[TBL] [Abstract][Full Text] [Related]
3. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
Stenman A; Zedenius J; Juhlin CC
Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
[TBL] [Abstract][Full Text] [Related]
4. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
5. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
[TBL] [Abstract][Full Text] [Related]
6. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
[TBL] [Abstract][Full Text] [Related]
8. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
9. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
10. Malignant pheochromocytoma: new malignancy criteria.
de Wailly P; Oragano L; Radé F; Beaulieu A; Arnault V; Levillain P; Kraimps JL
Langenbecks Arch Surg; 2012 Feb; 397(2):239-46. PubMed ID: 22069042
[TBL] [Abstract][Full Text] [Related]
11. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
[TBL] [Abstract][Full Text] [Related]
12. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
[TBL] [Abstract][Full Text] [Related]
13. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
[TBL] [Abstract][Full Text] [Related]
14. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
Jovanovic R; Kostadinova-Kunovska S; Bogoeva B; Spasevska L; Petrusevska G
Prilozi; 2012; 33(2):23-40. PubMed ID: 23425867
[TBL] [Abstract][Full Text] [Related]
15. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
16. Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation.
Cui Y; Ma X; Wang F; Wang H; Zhou T; Chen S; Tong A; Li Y
Endocr Pract; 2021 Apr; 27(4):348-353. PubMed ID: 34024343
[TBL] [Abstract][Full Text] [Related]
17. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
[TBL] [Abstract][Full Text] [Related]
18. Novel alternative tools for metastatic pheochromocytomas/paragangliomas prediction.
Cui Y; Zhou Y; Gao Y; Ma X; Wang Y; Zhang X; Zhou T; Chen S; Lu L; Zhang Y; Chang X; Tong A; Li Y
J Endocrinol Invest; 2024 May; 47(5):1191-1203. PubMed ID: 38206552
[TBL] [Abstract][Full Text] [Related]
19. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]